NAC (N-Acetyl Cysteine) — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
38 expert mentions
"Typical supplementation doses range from 600 milligrams to 1800 milligrams per day... I'd recommend starting low and building up."
Typical supplementation doses of NAC range from 600 milligrams to 1800 milligrams per day, and Huberman recommends starting low and building up.
"Typical supplementation doses range from 600 milligrams to 1800 milligrams per day... I'd recommend starting low and building up."
Typical supplementation doses of NAC range from 600 milligrams to 1800 milligrams per day, and Huberman recommends starting low and building up.
None of the 10 provided studies contain extractable key findings, populations, or limitations data, making direct comparison impossible. While some studies listed (e.g., PMID 35975308 on GlyNAC supplementation in older adults, PMID 39108325 on NAC for COPD) are nominally relevant to NAC use, no dosing data is available from these records to confirm or refute the 600–1800 mg/day range Huberman cites. The claim about dose titration ('starting low and building up') is a clinical practice recommendation that would require head-to-head dosing trials to assess, none of which are represented with usable data here.
"It's the antidote for acetaminophen overdose — it works by replenishing liver glutathione stores that get depleted by acetaminophen toxicity."
NAC is the established medical antidote for acetaminophen overdose, working by replenishing liver glutathione stores depleted by acetaminophen toxicity.
"It's the antidote for acetaminophen overdose — it works by replenishing liver glutathione stores that get depleted by acetaminophen toxicity."
NAC is the established medical antidote for acetaminophen overdose, working by replenishing liver glutathione stores depleted by acetaminophen toxicity.
None of the 10 provided studies directly address NAC's use as an antidote for acetaminophen overdose or its mechanism of replenishing hepatic glutathione in that context. While PMID 35975308 (GlyNAC RCT) touches on glutathione replenishment and PMID 37683986 reviews glutathione biochemistry, neither evaluates NAC in acetaminophen toxicity specifically. The claim itself is well-established in clinical toxicology and emergency medicine literature, but that evidence is simply not represented in the provided research corpus, making a direct evidence-based comparison impossible.
"a study combining NAC with glycine — called GlyNAC — which showed substantial improvements in multiple aging biomarkers in older adults including oxidative stress, mitochondrial function, inflammation, muscle strength, and cognitive function after 24 weeks."
A study combining NAC with glycine (GlyNAC) showed substantial improvements in multiple aging biomarkers in older adults, including oxidative stress, mitochondrial function, inflammation, muscle strength, and cognitive function after 24 weeks.
The claim is directly supported by PMID 35975308, an RCT titled 'Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks,' which aligns closely with Patrick's stated outcomes including oxidative stress, mitochondrial function, inflammation, and physical function over 24 weeks. However, the study is rated only 'moderate' quality, and no key findings, sample size, or limitations are provided in the retrieved metadata, preventing full verification of the specific magnitude of effects or whether cognitive function was explicitly measured. No other studies in the list directly address GlyNAC supplementation in aging, and the remaining studies are either unrelated (COPD, cancer chemotherapy, infertility) or address NAC alone in different contexts, offering no corroboration or contradiction of the specific GlyNAC combination claim.
"NAC supplementation can partially break this cycle."
NAC supplementation can partially break the cycle of oxidative stress driven by mitochondrial reactive oxygen species depleting glutathione with aging.
"the most compelling evidence for NAC is in the context of oxidative stress conditions — heavy exercise, pollution exposure, illness, and substance use."
The most compelling evidence for NAC supplementation in the general population is in the context of oxidative stress conditions — heavy exercise, pollution exposure, illness, and substance use.
"NAC supplementation can partially break this cycle."
NAC supplementation can partially break the cycle of oxidative stress driven by mitochondrial reactive oxygen species depleting glutathione with aging.
The most directly relevant study is PMID 35975308, an RCT examining GlyNAC (glycine + NAC) supplementation in older adults, which reported improvements in glutathione deficiency, oxidative stress, and mitochondrial dysfunction — directly relevant to the claim's core mechanism. However, this study tested a combination supplement, not NAC alone, making it difficult to attribute effects solely to NAC. The remaining studies in the provided literature either address unrelated conditions (COPD, OCD, cancer chemotherapy, contrast nephropathy) or lack reported key findings, limiting the ability to draw firm conclusions about NAC's isolated effect on the specific aging-related oxidative stress cycle described.
"It's also used in hospitals for certain kidney protection protocols and for dissolving mucus in patients with respiratory conditions like COPD."
NAC is used in hospitals for certain kidney protection protocols and for dissolving mucus in patients with respiratory conditions like COPD.
The expert's claim covers two specific clinical uses of NAC: kidney protection (contrast-induced nephropathy prophylaxis) and mucus dissolution in respiratory conditions like COPD. PMID 35636024, a strong-quality meta-analysis on prophylaxis against contrast-induced nephropathy, is directly relevant to the kidney protection claim, though its specific findings on NAC efficacy are not reported in the provided data. PMID 39108325, an RCT on NAC for acute exacerbation of COPD, is directly relevant to the respiratory claim, but again, key findings are not provided. The claim itself is well-established in clinical pharmacology literature, but the provided study summaries lack extractable key findings, limiting full verification from this specific evidence set.
"the most compelling evidence for NAC is in the context of oxidative stress conditions — heavy exercise, pollution exposure, illness, and substance use."
The most compelling evidence for NAC supplementation in the general population is in the context of oxidative stress conditions — heavy exercise, pollution exposure, illness, and substance use.
The claim that NAC is most compelling in oxidative stress contexts (heavy exercise, illness, etc.) finds some indirect support in the available literature. The meta-analysis (PMID: 35261035) examining NAC's effects on recovery biomarkers is directly relevant to the exercise context, and the GlyNAC RCT (PMID: 35975308) supports NAC's role in reducing oxidative stress and improving related markers. The COPD RCT (PMID: 39108325) speaks to illness-related oxidative stress. However, none of the retrieved studies provide direct key findings or population data as documented, limiting the ability to confirm Huberman's specific framing of 'most compelling evidence' being in these contexts versus others. The OCD review (PMID: 36384314) and infertility umbrella review (PMID: 39796491) actually suggest meaningful evidence exists in non-oxidative-stress domains, which complicates the claim's exclusivity.
"NAC has been studied for OCD, addiction, schizophrenia, and depression — conditions that share a common thread of oxidative stress and glutamate dysregulation. The evidence is mixed but promising enough that several research groups are running large trials."
NAC has been studied for OCD, addiction, schizophrenia, and depression — conditions that share oxidative stress and glutamate dysregulation — with mixed but promising evidence.
While one review (PMID: 36384314) specifically examines NAC for OCD-related disorders in children and adolescents, none of the provided studies directly address NAC's use across the full range of conditions claimed (OCD, addiction, schizophrenia, and depression) or explicitly discuss the oxidative stress and glutamate dysregulation mechanisms cited. The remaining studies cover unrelated or tangentially related topics such as COPD, contrast-induced nephropathy, cancer chemotherapy, and athletic recovery. Without access to the key findings of PMID: 36384314, it is not possible to confirm or deny the 'mixed but promising' characterization Huberman describes.
"Athletes who train intensely generate a lot of reactive oxygen species, and there's evidence that NAC can support recovery by maintaining antioxidant capacity."
There is evidence that NAC can support recovery in athletes who train intensely by maintaining antioxidant capacity.
The most directly relevant study in this set is the meta-analysis (PMID: 35261035) titled 'The effects of N-acetylcysteine on recovery biomarkers,' which by title aligns closely with Huberman's claim about NAC supporting athlete recovery; however, no key findings, population details, or limitations are reported for this study, limiting firm conclusions. The GlyNAC RCT (PMID: 35975308) supports NAC's role in improving glutathione deficiency and oxidative stress, but was conducted in older adults rather than athletes. The antioxidant supplementation review in soccer (PMID: 39599590) is tangentially relevant but lacks reported findings. Without accessible key findings from the most relevant meta-analysis, the claim has plausible mechanistic and indirect support but cannot be confirmed as strongly evidence-backed from this literature set alone.
"a study combining NAC with glycine — called GlyNAC — which showed substantial improvements in multiple aging biomarkers in older adults including oxidative stress, mitochondrial function, inflammation, muscle strength, and cognitive function after 24 weeks."
A study combining NAC with glycine (GlyNAC) showed substantial improvements in multiple aging biomarkers in older adults, including oxidative stress, mitochondrial function, inflammation, muscle strength, and cognitive function after 24 weeks.
"It's also used in hospitals for certain kidney protection protocols and for dissolving mucus in patients with respiratory conditions like COPD."
NAC is used in hospitals for certain kidney protection protocols and for dissolving mucus in patients with respiratory conditions like COPD.
"Athletes who train intensely generate a lot of reactive oxygen species, and there's evidence that NAC can support recovery by maintaining antioxidant capacity."
There is evidence that NAC can support recovery in athletes who train intensely by maintaining antioxidant capacity.
"NAC has been studied for OCD, addiction, schizophrenia, and depression — conditions that share a common thread of oxidative stress and glutamate dysregulation. The evidence is mixed but promising enough that several research groups are running large trials."
NAC has been studied for OCD, addiction, schizophrenia, and depression — conditions that share oxidative stress and glutamate dysregulation — with mixed but promising evidence.
"Glutathione is synthesized in virtually every cell and is critical for neutralizing reactive oxygen species, detoxifying heavy metals and drugs, and maintaining immune function."
Glutathione is synthesized in virtually every cell and is critical for neutralizing reactive oxygen species, detoxifying heavy metals and drugs, and maintaining immune function.
The expert's claim describes well-established biochemistry of glutathione—its ubiquitous cellular synthesis, role in neutralizing reactive oxygen species, detoxification of heavy metals and drugs, and immune function support. While this claim is consistent with foundational biochemical science, none of the 10 provided studies directly test or confirm these specific mechanistic assertions. The studies focus largely on N-acetylcysteine (a glutathione precursor) in clinical contexts such as COPD, OCD, aging, and sports recovery, and one GlyNAC RCT (PMID: 35975308) tangentially supports glutathione's role in oxidative stress and aging hallmarks, but none directly validate the breadth of the mechanistic claim as stated.
"NAC — N-acetyl cysteine — is a precursor to glutathione, which is the body's master antioxidant."
NAC is a precursor to glutathione, the body's master antioxidant.
"NAC — N-acetylcysteine — is one of the most effective oral methods for raising glutathione because it provides cysteine, the rate-limiting amino acid for glutathione synthesis."
NAC is one of the most effective oral methods for raising glutathione because it provides cysteine, the rate-limiting amino acid for glutathione synthesis.
"NAC's ability to restore glutathione may be one mechanism by which it has anti-inflammatory effects, which is relevant for conditions ranging from COPD to liver disease to psychiatric disorders."
NAC's ability to restore glutathione may be one mechanism by which it has anti-inflammatory effects, relevant for conditions including COPD, liver disease, and psychiatric disorders.
"NAC has a protective acetyl group that stabilizes cysteine in circulation and allows it to be taken up by cells for glutathione synthesis."
NAC has a protective acetyl group that stabilizes cysteine in circulation and allows it to be taken up by cells for glutathione synthesis.
The expert's claim describes the pharmacokinetic mechanism by which NAC acts as a cysteine prodrug — specifically that the acetyl group stabilizes cysteine in circulation and facilitates cellular uptake for glutathione synthesis. None of the 10 provided studies contain key findings or methodological details that directly address this mechanistic claim. While the GlyNAC RCT (PMID: 35975308) and glutathione review (PMID: 37683986) are topically relevant and could plausibly touch on this mechanism, no extractable data from these sources is available to confirm or refute the claim. The claim itself is well-established in basic biochemistry literature, but that supporting evidence is not represented in the provided research corpus.
"NAC has a protective acetyl group that stabilizes cysteine in circulation and allows it to be taken up by cells for glutathione synthesis."
NAC has a protective acetyl group that stabilizes cysteine in circulation and allows it to be taken up by cells for glutathione synthesis.
"NAC — N-acetylcysteine — is one of the most effective oral methods for raising glutathione because it provides cysteine, the rate-limiting amino acid for glutathione synthesis."
NAC is one of the most effective oral methods for raising glutathione because it provides cysteine, the rate-limiting amino acid for glutathione synthesis.
The expert's claim that NAC raises glutathione by supplying cysteine (the rate-limiting amino acid) is a well-established biochemical mechanism taught in pharmacology, but the provided studies do not directly test or confirm this claim with usable key findings. The GlyNAC RCT (PMID: 35975308) is the most relevant study listed, as it examined NAC supplementation alongside glycine in older adults and reportedly assessed glutathione levels, but no key findings were extracted, preventing direct evidentiary support. The remaining studies address unrelated topics (COPD exacerbations, contrast nephropathy, cancer chemotherapy sequencing) or lack extractable data to assess the specific mechanistic claim.
"The rationale is that glycine is the other rate-limiting amino acid for glutathione, and providing both precursors together is more effective than either alone."
Providing both NAC and glycine together is more effective than either alone for glutathione synthesis, because glycine is also a rate-limiting amino acid for glutathione.
"NAC's ability to restore glutathione may be one mechanism by which it has anti-inflammatory effects, which is relevant for conditions ranging from COPD to liver disease to psychiatric disorders."
NAC's ability to restore glutathione may be one mechanism by which it has anti-inflammatory effects, relevant for conditions including COPD, liver disease, and psychiatric disorders.
The expert's mechanistic claim that NAC restores glutathione and thereby exerts anti-inflammatory effects is biologically plausible and directionally supported by several studies in the provided list. The GlyNAC RCT (PMID: 35975308) explicitly examined glutathione deficiency, oxidative stress, and inflammation outcomes, providing some direct mechanistic support. The COPD RCT (PMID: 39108325) and the OCD review (PMID: 36384314) address specific disease areas Patrick mentions, lending condition-specific relevance. However, the published abstracts in this dataset lack reported key findings, effect sizes, or sample sizes, making it impossible to confirm the strength or consistency of the glutathione-inflammation linkage across conditions with high confidence.
"The rationale is that glycine is the other rate-limiting amino acid for glutathione, and providing both precursors together is more effective than either alone."
Providing both NAC and glycine together is more effective than either alone for glutathione synthesis, because glycine is also a rate-limiting amino acid for glutathione.
The expert's mechanistic claim that glycine is also rate-limiting for glutathione synthesis (alongside cysteine) is biologically plausible and consistent with established biochemistry, and PMID 35975308 — an RCT of GlyNAC supplementation in older adults — directly tested the combination and reported improvements in glutathione deficiency, lending indirect support to the claim that the combination is more effective than either alone. However, none of the provided studies contain explicit comparative data (GlyNAC vs. NAC alone vs. glycine alone) that would confirm the 'more effective than either alone' assertion with rigorous head-to-head evidence. The remaining studies are either unrelated to this mechanistic question or lack reported key findings.
"NAC is essentially a more bioavailable way to deliver cysteine, the rate-limiting amino acid for glutathione synthesis."
NAC is a more bioavailable way to deliver cysteine, the rate-limiting amino acid for glutathione synthesis.
The expert's claim that NAC is a more bioavailable way to deliver cysteine for glutathione synthesis is a well-established biochemical principle in pharmacology, but none of the provided studies directly test or report on NAC's comparative bioavailability versus free cysteine. The GlyNAC RCT (PMID: 35975308) is most relevant, as it used NAC supplementation and measured glutathione levels in older adults, implicitly supporting that NAC raises glutathione, but it does not address bioavailability comparisons directly. The remaining studies either lack reported key findings, are off-topic (e.g., cancer chemotherapy economics, contrast-induced nephropathy), or address NAC in unrelated clinical contexts.
"NAC is essentially a more bioavailable way to deliver cysteine, the rate-limiting amino acid for glutathione synthesis."
NAC is a more bioavailable way to deliver cysteine, the rate-limiting amino acid for glutathione synthesis.
"NAC — N-acetyl cysteine — is a precursor to glutathione, which is the body's master antioxidant."
NAC is a precursor to glutathione, the body's master antioxidant.
The claim that NAC is a precursor to glutathione is a well-established biochemical mechanism, and the GlyNAC RCT (PMID: 35975308) directly supports this by demonstrating that supplementing with glycine and NAC in older adults improves glutathione deficiency, providing clinical evidence that NAC contributes to glutathione synthesis in humans. The characterization of glutathione as the body's 'master antioxidant' is supported conceptually by the review on glutathione and glutathione-dependent enzymes (PMID: 37683986), which addresses glutathione's central biochemical role. However, none of the retrieved studies contain extractable key findings confirming the mechanistic claim explicitly, and the evidence base here is largely indirect, with several studies focused on unrelated outcomes (e.g., COPD exacerbations, contrast-induced nephropathy, cancer chemotherapy).
"Glutathione is synthesized in virtually every cell and is critical for neutralizing reactive oxygen species, detoxifying heavy metals and drugs, and maintaining immune function."
Glutathione is synthesized in virtually every cell and is critical for neutralizing reactive oxygen species, detoxifying heavy metals and drugs, and maintaining immune function.
"I take 600 to 1200 milligrams of NAC per day, often combined with glycine."
Rhonda Patrick personally takes 600 to 1200 milligrams of NAC per day, often combined with glycine.
The claim is a personal anecdote about Rhonda Patrick's own supplement regimen (600–1200 mg NAC daily, often with glycine), which by definition cannot be confirmed or refuted by published research. The most directly relevant study in the provided list (PMID: 35975308) is an RCT examining GlyNAC (glycine + NAC) supplementation in older adults, which lends biological plausibility to the combination she describes, but it does not validate or address her personal dosing practices. None of the remaining studies provide evidence bearing on whether this specific dosage regimen in a healthy individual is effective or safe for the purposes she may intend.
"I take 600 to 1200 milligrams of NAC per day, often combined with glycine."
Rhonda Patrick personally takes 600 to 1200 milligrams of NAC per day, often combined with glycine.
"High doses can cause nausea and GI upset."
High doses of NAC can cause nausea and GI upset.
None of the 10 provided studies report key findings, populations, or limitations that directly address the side effect profile of high-dose NAC supplementation, including nausea and GI upset. While several studies involve NAC (PMIDs 39108325, 35975308, 36384314, 40421021, 35261035), their extracted data fields are empty, making it impossible to assess whether adverse GI effects were documented or reported. The claim itself is a well-recognized caution found in clinical pharmacology and prescribing literature, but the specific evidence base provided here does not support or contradict it.
"the FDA briefly attempted to remove NAC from the supplement market after a company tried to patent it as a drug. It's currently still available as a supplement, but this regulatory uncertainty is worth tracking."
The FDA briefly attempted to remove NAC from the supplement market after a company tried to patent it as a drug, and this regulatory uncertainty is worth tracking.
"High doses can cause nausea and GI upset."
High doses of NAC can cause nausea and GI upset.
"the FDA briefly attempted to remove NAC from the supplement market after a company tried to patent it as a drug. It's currently still available as a supplement, but this regulatory uncertainty is worth tracking."
The FDA briefly attempted to remove NAC from the supplement market after a company tried to patent it as a drug, and this regulatory uncertainty is worth tracking.
None of the 10 provided PubMed studies address the regulatory history of NAC, FDA actions regarding its classification, or patent-related market removal attempts. The claim is about a specific regulatory and legal event — not NAC's pharmacological or clinical properties — and is therefore entirely outside the scope of the supplied research literature. While the FDA's 2020–2021 regulatory uncertainty around NAC as a supplement is a documented public regulatory matter (based on external knowledge), the provided studies offer no evidentiary basis to support, contradict, or qualify this claim.
"NAC smells terrible — like sulfur — which is a sign of its sulfur-containing cysteine backbone."
NAC smells like sulfur due to its sulfur-containing cysteine backbone.
"NAC smells terrible — like sulfur — which is a sign of its sulfur-containing cysteine backbone."
NAC smells like sulfur due to its sulfur-containing cysteine backbone.
None of the 10 published studies provided address the organoleptic properties of NAC or its sulfur-containing chemical structure in any measurable way. The claim is a basic chemistry statement — that NAC contains a thiol (sulfhydryl) group derived from cysteine, which is responsible for its characteristic sulfurous odor — but none of the retrieved literature (covering topics such as COPD treatment, GlyNAC supplementation, OCD, and contrast-induced nephropathy) contains findings relevant to this assertion. While the chemistry underlying the claim is well-established in biochemistry literature, the specific studies provided here offer no direct or indirect evidence to evaluate it.